Funding for this research was provided by:
Takeda Pharmaceutical Company
Text and Data Mining valid from 2019-09-24
First Online: 24 September 2019
Compliance with Ethical Standards
: This study was funded by Takeda Pharmaceutical Company Ltd. in Tokyo, Japan.
: This study was funded by Takeda Pharmaceutical Company Ltd. in Tokyo, Japan. LH, AS, HB, KF and MK are all employees of Evidera, which provides consulting and other research services to pharmaceutical, medical device, and other organizations. In their salaried positions, they work with a variety of companies and are precluded from receiving payment or honoraria directly from these organizations for services rendered. Evidera received funding from Takeda Pharmaceutical Company Ltd. in Tokyo, Japan for the involvement of their employees. HK and RI are employed by Takeda Pharmaceutical Company Ltd. in Tokyo, Japan, and HK owns stocks in Takeda Pharmaceutical Company Ltd. KY was employed by Takeda Pharmaceutical Company Ltd. in Tokyo, Japan at the time the study was conducted. RI joined Takeda in January 2018; before joining Takeda, RI was an Associate Clinical Professor at the Department of Gastrointestinal Endoscopy and Internal Medicine at Saga University in Japan. RI is a key opinion leader in inflammatory bowel diseases and has authored/co-authored over 150 publications.
: Luis Hernandez will serve as overall guarantor for this study and article.
: For this type of study, formal consent is not required, so we did not submit our study to an independent ethics committee or institutional review board. This article does not contain any studies with human participants or animals performed by any of the authors.
: Informed consent procedures were not applicable to this study.